About Aelis Farma

Aelis Farma mission: Develop the therapeutic potential of CB1-SSi

CB1 Signaling Specific inhibitors (CB1-SSi) are a proprietary new pharmacological class never tested in humans before that open a new frontier in pharmacology.

CB1-SSi have a unique mechanism of action
CB1-SSi are new molecular entities (NME) that mimicking a natural defense mechanism of the brain (Science 2014). CB1-SSi do not block, like available antagonists, all the cellular activities of a receptor.
CB1-SSi correct selectively the cellular activity hyperactivated in the pathological state. CB1-SSi do not modifying normal physiology or behavior and have no identifiable toxicity and side effects.

CB1-SSi have broad therapeutic targets:
CB1-SSi modify the principal target of cannabinoid therapeutics, the CB1 receptor, which is involved in a large spectrum of diseases of the central nervous system and peripheral organs.